Mevion has designed a high energy proton source – the world’s first superconducting synchrocyclotron – that dramatically reduces the size, cost, and complexity of proton acceleration. Powered by a gantry-mounted TriNiobium Core™, the MEVION S250 has a footprint only slightly larger than a conventional linac, yet delivers the incredible targeting advantages of proton therapy with higher throughput. The result is a truly elegant cancer care solution, as economical as it is precise.

Optimal dose distribution – the ultimate goal of radiation therapy devices and practice – is the intrinsic value of proton therapy. The MEVION S250 delivers on the therapeutic promise of high energy particle radiation by mounting the TriNiobium Core on the industry’s first concentric gantry, resulting in higher isocentric accuracy. When combined with full robotic positioning, multidimensional imaging, and Mevion’s fourth-generation DirectDose™ beam modulating system, a level of radiation-targeting precision is achieved that is not possible with traditional devices.

The MEVION S250 Proton Therapy System is USFDA 510(k) cleared and complies with MDD/CE requirements